

IP Strategies for Health Sciences Startups

APRIL 1, 2014

Biotech and medical device companies are heavily dependent on intellectual property rights, particularly those developing diagnostic, therapeutic or invasive products. The complexity of the technology and rapidly evolving legal landscape make the availability, validity and enforceability of biotech patents highly uncertain. This session, led by Michael Twomey, a patent attorney and partner at WilmerHale, will explore some of the basic IP questions facing health sciences startups.


[READ MORE ABOUT THE EVENT](#)

Related Solutions

Emerging Company and
Venture Capital

Intellectual Property
Counseling and Prosecution

You May Be Interested In



41st Annual Representing and Managing Tax-Exempt Organizations Conference

APRIL 18–19, 2024

SPEAKING ENGAGEMENT



Cybersecurity and Privacy Protection Conference 2024

APRIL 18–19, 2024

SPEAKING ENGAGEMENT



Managing Cyber Risks in 2024: Regulatory Compliance, Litigation Risk, Third-Party Cybersecurity Incident Exposure

APRIL 24, 2024

SPEAKING ENGAGEMENT

[VIEW ALL EVENTS](#)